| Dr Laura B Schield, MD | |
|
2787 97th Ave Nw, Bismarck, ND 58503-8452 | |
| (701) 223-0592 | |
| Not Available |
| Full Name | Dr Laura B Schield |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 33 Years |
| Location | 2787 97th Ave Nw, Bismarck, North Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124064431 | NPI | - | NPPES |
| 054517 | Medicaid | ND | |
| P00113732 | Other | ND | RR MEDICARE |
| 021724 | Other | ND | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0804X | Psychiatry & Neurology - Child & Adolescent Psychiatry | 7523 (North Dakota) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lake Region Human Service Center | 8426941436 | 8 |
| University Of North Dakota | 2961395934 | 22 |
News Archive
Although they look normal, people suffering from body dysmorphic disorder (BDD) perceive themselves as ugly and disfigured.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.
› Verified 9 days ago
| Entity Name | Badlands Human Service Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124072525 PECOS PAC ID: 9739085499 Enrollment ID: O20031211000947 |
News Archive
Although they look normal, people suffering from body dysmorphic disorder (BDD) perceive themselves as ugly and disfigured.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.
› Verified 9 days ago
| Entity Name | University Of North Dakota |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619905528 PECOS PAC ID: 2961395934 Enrollment ID: O20040204000241 |
News Archive
Although they look normal, people suffering from body dysmorphic disorder (BDD) perceive themselves as ugly and disfigured.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.
› Verified 9 days ago
| Entity Name | Lake Region Human Service Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669411930 PECOS PAC ID: 8426941436 Enrollment ID: O20040204000457 |
News Archive
Although they look normal, people suffering from body dysmorphic disorder (BDD) perceive themselves as ugly and disfigured.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.
› Verified 9 days ago
| Entity Name | West Central Human Service Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226713 PECOS PAC ID: 6002801107 Enrollment ID: O20040419000160 |
News Archive
Although they look normal, people suffering from body dysmorphic disorder (BDD) perceive themselves as ugly and disfigured.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.
› Verified 9 days ago
| Entity Name | South Central Human Service Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225075906 PECOS PAC ID: 2365420262 Enrollment ID: O20040708000481 |
News Archive
Although they look normal, people suffering from body dysmorphic disorder (BDD) perceive themselves as ugly and disfigured.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.
› Verified 9 days ago
| Entity Name | Northeast Human Service Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366496341 PECOS PAC ID: 1658341441 Enrollment ID: O20040729000033 |
News Archive
Although they look normal, people suffering from body dysmorphic disorder (BDD) perceive themselves as ugly and disfigured.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.
› Verified 9 days ago
| Entity Name | Northwest Human Service Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770524613 PECOS PAC ID: 4183683196 Enrollment ID: O20041006000330 |
News Archive
Although they look normal, people suffering from body dysmorphic disorder (BDD) perceive themselves as ugly and disfigured.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.
› Verified 9 days ago
| Entity Name | Southeast Human Service Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932146941 PECOS PAC ID: 8527027556 Enrollment ID: O20041006000512 |
News Archive
Although they look normal, people suffering from body dysmorphic disorder (BDD) perceive themselves as ugly and disfigured.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.
› Verified 9 days ago
| Entity Name | North Central Human Service Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477592533 PECOS PAC ID: 6305885013 Enrollment ID: O20050624000207 |
News Archive
Although they look normal, people suffering from body dysmorphic disorder (BDD) perceive themselves as ugly and disfigured.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Laura B Schield, MD 2787 97th Ave Nw, Bismarck, ND 58503-8452 Ph: (701) 223-0592 | Dr Laura B Schield, MD 2787 97th Ave Nw, Bismarck, ND 58503-8452 Ph: (701) 223-0592 |
News Archive
Although they look normal, people suffering from body dysmorphic disorder (BDD) perceive themselves as ugly and disfigured.
NOXXON Pharma today announced the initiation of a Phase I clinical trial for NOX-H94, the Company's third compound to enter the clinic. NOX-H94 is a Spiegelmer designed to treat anemia of chronic disease by targeting the peptide hormone hepcidin, the key regulator of iron metabolism.
Using advanced MRI and an artificial intelligence technique, researchers in Geneva, Switzerland, have identified a method that may help identify which individuals with mild cognitive impairment (MCI) will continue to decline, according to a study published online and in the December issue of Radiology.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Lamivudine and Zidovudine Tablets, 30 mg/60 mg.
› Verified 9 days ago
Dr. Jess A Miller, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 222 N 7th St, Bismarck, ND 58501 Phone: 701-323-5422 Fax: 701-323-8645 | |
Stephanie Ann Lill Miller, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2830 N Washington St, Bismarck, ND 58503 Phone: 701-323-6000 | |
Cheryl E Huber, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1800 E Interstate Ave Ste B, Bismarck, ND 58503 Phone: 701-323-6543 | |
Gabriela Balf-soran, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3501 Chisholm Trl, Bismarck, ND 58503 Phone: 203-707-0881 Fax: 701-425-0596 | |
Dr. Bryon Lee Herbel, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 303 N 4th St, Bismarck, ND 58501 Phone: 701-223-2425 | |
John Riedinger, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 4535 Northern Sky Dr, Bismarck, ND 58503 Phone: 701-323-8700 |